The SAGE Encyclopedia of Stem Cell Research. Группа авторов

Чтение книги онлайн.

Читать онлайн книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов страница 62

Жанр:
Серия:
Издательство:
The SAGE Encyclopedia of Stem Cell Research - Группа авторов

Скачать книгу

Patients were those suffering from the chronic disease who had become resistant, intolerant, or who were unresponsive to other forms of treatment. While no adverse effects were reported, there also appeared to be a lack of beneficial effects in patients at eight weeks post-treatment, but the company holds out hope for those patients receiving additional MultiStem treatments over time.

      Competing Companies

      With the explosion of promising findings in stem cell research, there has also been a multitude of start-up companies. Some of these competing in the stem cell market in 2014 include Fate Therapeutics, Cytori, StemCells Inc., Aastrom, ViaCyte, ReNeuron, Neuralstem, OncoMed, Orgenesis, Cellular Dynamics, Neostem, AlloOnc, Advanced Cell Technology, BioTime, Mesoblast, and Pluristem Therapeutics. However, primary competition for Athersys’s MultiStem includes products being developed by the companies Mesoblast and Pluristem Therapeutics. Osirus was another key competitor of Athersys, but it exited the stem cell arena in late 2013, selling its stem cell platform, specifically mesenchymal stem cell–based therapeutic research, to Mesoblast in 2013. Mesoblast has taken that research and is developing stem cell products for the treatment of heart failure, Crohn’s disease, orthopedics, and acute graft-versus-host disease. On the other hand, it appears that Pluristem is focusing on placenta-based cell science for their development of therapeutic products, including various inflammatory and ischemic conditions, in part using a proprietary three-dimensional cell-expansion technology.

      Astra I. Chang

       University of California, Davis

      See Also: Adult Stem Cells: Overview; Case Western Reserve University/Cleveland Clinic; Mesenchymal Stem Cells; Stem Cell Companies: Overview.

      Further Readings

      Athersys Inc. “Athersys Announces Results From Phase 2 Study of MultiStem Cell Therapy for Ulcerative Colitis.” April 28, 2014. http://www.athersys.com/releasedetail.cfm?ReleaseID=842936.

      Harrington, J. J., B. Sherf, S. Rundlett, et al. “Creation of Genome-Wide Protein Expression Libraries Using Random Activation of Gene Expression.” Nature Biotechnology, v.19/5 (2001).

      Werner, M., T. Mayleben, and G. Van Bokkelen. “Autologous Cell Therapies: The Importance of Regulatory Oversight.” Regenerative Medicine, v.7/6 Suppl (2013).

      Australia

      Australia

      61

      64

      Australia

      Australia has one of the most supportive stem cell research environments in the world, and researchers have made great strides in conducting innovative stem cell research and developing therapies for a host of diseases and conditions. In the early 1980s, Australian researchers were among the first in the world to use fertility drugs that led to live births. In 2001, the national government launched Backing Australia’s Ability, earmarking $3 billion for policy initiatives that included a new focus on stem cell research. In 2003, the government announced that it was investing $110 million over a 10-year period to establish Stem Cell Australia. That effort brought together experts from all of Australia to promote all aspects of stem cell research. In 2011, as funding for Stem Cell Australia reached the end of its cycle, the National Stem Cell Foundation of Australia was created to raise funds to continue the work begun by the government initiative.

      While most Australians express support for using embryonic stem cells in research, the use of human embryonic cells remains controversial. In 2006, the government allotted an additional $22 million to establish the National Centre for Adult Stem Cell Research at the Eskitis Institute for Cell and Molecular Therapies at Griffith University in Queensland, bypassing the ethics debate. Professor Alan Mackay-Sim, an internationally recognized neurobiologist and expert on differentiating nasal stem cells, was appointed to head the facility, which focuses on developing stem cell therapies for neurological diseases and injuries.

      In 2010, researchers were invited to apply for new competitive funding totaling $21 million. Local and regional stem cell organizations such as the NSW Stem Cell Network in New South Wales also contribute to the stem cell research community. Private and public foundations and biotech companies such as BresaGen Ltd, ES Cell International Pte Ltd, Norwood Abbey Ltd, and Stem Cell Sciences Pty Ltd are also engaged in various aspects of stem cell research.

      Background

      In the 1980s, Australian researchers began making significant discoveries in stem cell research. Teams that included Bik To and Chris Juttner of the Institute of Medical and Veterinary Science and the Royal Adelaide Hospital and a team led by Don Metcalf at WEHI /Royal Melbourne Hospital demonstrated that hematopoietic stem cells have the ability to mobilize into peripheral blood. Alan Trounson was involved in the early stages of in vitro fertilization (IVF) research that led to the birth of the first in vitro fertilization babies born in Australia. Perry Bartlett identified renewable brain cells, and Nick Gough led his team to identify the leukemia inhibitory factor (LIF) that results in a pluripotent state in the stem cells of mice.

      Two of the most significant contributions to stem cell research were the findings of Alan Metcalf and his colleagues at the Walter and Eliza Hall Institute in Melbourne involving the regulation of the immune system by growth factors and signaling pathways and the identification of the relationships between hematopoietic stem cells and their offspring. By 1998, researchers, including Alan Trounson and Martin Pera, were advocating the use of embryonic stem cells for developing treatments for disease and severe injuries. A consortium of Australian and Singaporean researchers created some of the first hES cell lines and established Embryonic Stem Cell International.

      In the early 21st century, following the mapping of the human genome, Australia joined other industrialized nations in accelerating the pace of stem cell research. Australia became one of the first countries in the world to develop a strategy for bringing local and regional governments and private industries into the emerging field. With the new focus on stem cell research, ethical debates heightened. In 2002, Parliament passed the Research Involving Human Embryos Act and the Prohibition of Human Cloning Act. Like the British system on which Australia is based, members of Parliament (MPs) are expected to vote strictly along party lines. However, MPs were allowed to vote according to conscience on the two stem cell laws. Together, the acts prohibited any form of human cloning and placed strict regulations on how excess human embryos were to be handled. Scientists were still allowed to conduct research on human embryos that had been created on or before April 15, 2002. With a three-year moratorium on cloning in place, Parliament stipulated that the laws would be revisited in three years to address new advances in stem cell research. Top researchers began pressuring the government to create a state-sponsored facility to conduct stem cell research.

Image 8

      Founded in 2003, The Australian Stem Cell Centre focuses on regenerative medicine through the use of stem cells. In 2008, the center began working with induced pluripotent (iPS) cells—artificially created embryonic stem cells. (Australian Stem Cell Center)

      Significant changes took place in the Australian stem cell research community when the issue of embryonic stem cell research was reviewed in 2005, and Parliament passed the Reregulation of Human Embryos Research Act the following year. Somatic cell nuclear transfer, which had been banned in 2002, became legal but was still

Скачать книгу